text stringlengths 1 654k |
|---|
We can order this in for you |
How long will it take? |
Add this item to my basket |
Aquarium Fish |
978/184/477/9781844770243.jpg |
Aquarium Fish |
Mary Bailey, Gina Sandford |
Fishes & aquaria |
Paperback |
A comprehensive practical guide to setting up all types of aquaria, with 700 step-by-step photographs. [more] |
$23.95 |
We can order this in for you |
How long will it take? |
Add this item to my basket |
Trout of the World |
978/161/769/9781617690235.jpg |
Trout of the World |
James Prosek |
Fishes & aquaria |
Hardback |
An updated introduction... [more] |
$45.00 |
We can order this in for you |
How long will it take? |
Add this item to my basket |
Marine Aquarium Keeping |
978/047/159/9780471594895.jpg |
Marine Aquarium Keeping |
Stephen Spotte |
Aquaculture & fish-farming: practice & techniques; Fishes & aquaria |
Paperback |
The science and common sense behind creating an inexpensive, flourishing marine aquarium Marine Aquarium Keeping is the first... [more] |
$122.95 |
We can order this in for you |
How long will it take? |
Add this item to my basket |
Saltwater Aquariums For Dummies |
978/111/961/9781119612681.jpg |
Saltwater Aquariums For Dummies |
Gregory Skomal |
Fishes & aquaria |
Paperback |
Demystifies aquarium setup and maintenance Combine and care for a wide variety of marine fish and invertebrates Dive into... [more] |
$46.95 |
Forthcoming |
Pre-Order now |
Add this item to my basket |
1 |
My Shopping Basket |
Your cart does not contain any items. |
New Safety Concerns for Osteoarthritis Drug |
By Pat Anson, PNN Editor |
Disappointing results from a Phase 3 clinical study are raising new safety concerns about an experimental class of pain-relieving drugs once considered a promising alternative to opioids. |
Pfizer and Eli Lilly say 6.3% of osteoarthritis patients taking a 5 mg dose of tanezumab experienced rapidly progressive osteoarthritis in their joints. There was significant improvement in their pain and physical function, but the patients’ overall assessment of their condition was no better than those treated with no... |
Patients taking a lower 2.5 mg dose of tanezumab did not have any significant improvement in their pain, quality of life or overall condition. And 3.2% experienced rapidly progressive osteoarthritis. |
bigstock-Minority-Doctor-2964756.jpg |
“We are analyzing these findings in the context of the recent Phase 3 results as we assess potential next steps for tanezumab,” Ken Verburg, Pfizer Global Product Development, said in a statement. “We plan to review the totality of data from our clinical development program for tanezumab with regulatory authorities.” |
Tanezumab is a humanized monoclonal antibody that targets nerve growth factor (NGF), a protein that increases as a result of injury, inflammation or chronic pain. Tanezumab binds to NGF and inhibits pain signals from reaching the brain. |
Tanezumab was considered so promising a therapy that it was given fast track designation from the FDA in 2017, a process that speeds up the development of new therapies to treat serious conditions. |
Ironically, it was the FDA that slowed the development of NGF inhibitors in 2010 because of concerns that tanezumab made osteoarthritis worse in some patients. Most clinical studies of tanezumab did not resume until 2015. |
The reappearance of the same safety issue and the marginal pain relief provided by tanezumab could be the last straw for the drug, according to one analyst. |
“It is hard for us to imagine how these results could have been much worse. Pfizer indicated that they ‘plan to review the totality of data’ with regulatory authorities, which suggests to us that the co-sponsors will try to find a way to resurrect the program for some subset or sub-population of patients, but recognize... |
A clinical study of fasinumab, another NGF inhibitor being developed by Teva and Regeneron Pharmaceuticals, was stopped by the FDA in 2016 after a patient showed signs of severe joint disease. Regeneron and Teva are continuing to study fasinumab in patients with chronic low back pain. |
Pfizer and Eli Lilly are also studying tanezumab as a treatment for low back pain, and reported promising results from a Phase 3 trial in February. Rapidly progressive osteoarthritis was also reported in a small number of patients involved in that study. |
For many businesses, your brand will be a crucial part of the identity of your business. Customers will often identify your business by reference to your logo, slogan, colour scheme or even a distinctive sound. The best way to protect these distinctive elements of your brand is by obtaining a registered trade mark. It ... |
LegalVision’s trade mark lawyers can assist you with: |
• registering a trade mark in Australia and overseas; |
• responding to a trade mark opposition; |
• defending a trade mark infringement claim; |
• renewing a trade mark; and |
• lodging a trade mark infringement. |
Registering a trade mark can be a lengthy process. It involves classifying your brand into one of IP Australia’s 45 classes and conducting a comprehensive trade mark search before making your application. Our trade mark lawyers have successfully registered hundreds of trade marks in Australia and overseas and can assis... |
Make an Enquiry |
• We will be in touch shortly with a quote. By submitting this form, you agree to receive emails from LegalVision and can unsubscribe at any time. See our full Privacy Policy. |
• This field is for validation purposes and should be left unchanged. |
5 Things You Need to Know About Trade Marks |
• 1A trade mark is a way of protecting your brand, whether it be a brand name, logo or other distinctive element which distinguishes your business. By trade marking the name or logo you use to provide your products or services, you are distinguishing your brand from your competitors. Trade marking gives you rights ag... |
• 2For smaller businesses, trade marking shows that you have taken steps to establish and protect your brand. It can be an effective strategy to provide your business with legitimacy in the eyes of customers. A ™ or ® next to your brand name can reassure potential investors, business partners and customers that your ... |
• 3The first step in registering a trade mark is to check whether the name you’re looking to use is already in use by someone else. Your trade mark attorney, consultant or lawyer can perform a variety of searches to see whether a trader is already using the name that you wish to trade mark. If those searches don’t re... |
• 4Submitting an application requires the applicant to choose which of the 45 classes you wish to trade mark in. Classes are divided up along product and service lines. You should only register a trade mark in a class that is relevant to your products or services as each class that you wish to register your trade mar... |
• 5Once your trade mark attorney, consultant or lawyer submits your application, a number of issues may arise, including objections from competitors, questions from IP Australia. If this process is navigated effectively, your registration will be complete by around seven and half months after the initial application ... |
Get in Touch |
Fill out the form below and a LegalVision team member will be in touch shortly! |
• We will be in touch shortly with a quote. By submitting this form, you agree to receive emails from LegalVision and can unsubscribe at any time. See our full Privacy Policy. |
• This field is for validation purposes and should be left unchanged. |
Our Awards |
• Top 20 Startups in Australia - 2018 LinkedIn Startups List Top 20 Startups in Australia - 2018 LinkedIn Startups List |
• NewLaw Firm of the Year – 2019 Australian Law Awards NewLaw Firm of the Year – 2019 Australian Law Awards |
• Law Firm of the Year Finalist – 2018 Australasian Law Awards Law Firm of the Year Finalist – 2018 Australasian Law Awards |
• AFR Fast 100 List – 2018 Australian Financial Review AFR Fast 100 List – 2018 Australian Financial Review |
• NewLaw Firm of the Year – 2017 Australian Law Awards NewLaw Firm of the Year – 2017 Australian Law Awards |
• Most Innovative Law Firm - 2019 Australasian Lawyer Most Innovative Law Firm - 2019 Australasian Lawyer |
Privacy Policy Snapshot |
We collect and store information about you. Let us explain why we do this. |
What information do you collect? |
We collect a range of data about you, including your contact details, legal issues and data on how you use our website. |
How do you collect information? |
We collect information over the phone, by email and through our website. |
What do you do with this information? |
We store and use your information to deliver you better legal services. This mostly involves communicating with you, marketing to you and occasionally sharing your information with our partners. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.